ArticleBiology open2017
Innovative approaches to establish and characterize primary cultures: an
Erratum issuedAbstract read
In one paragraph
Article in Biology open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Tumorigenesis of well-differentiated and dedifferentiated liposarcoma: 12q amplicon architecture, oncogenic cargo, and evolutionary progression.Cancer metastasis reviews · 2026Review
- Natural products modulate social behavior and gut microbiota in a valproic acid-induced zebrafish model of autism spectrum disorder.Biomolecules & biomedicine · 2026Article
- Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research.Oncology research · 2025Review
- Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.Biomedicines · 2024Review
- P53 Activation Promotes Maturational Characteristics of Pluripotent Stem Cell-Derived Cardiomyocytes in 3-Dimensional Suspension Culture Via FOXO-FOXM1 Regulation.Journal of the American Heart Association · 2024Article
- Advantages of the zebrafish tumor xenograft model: the evaluation of efficacy in cancer therapy and the application to the study of lncRNAs.Frontiers in immunology · 2024Review
- What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.Cancers · 2022Review
- The emerging role of cancer nanotechnology in the panorama of sarcoma.Frontiers in bioengineering and biotechnology · 2022Review
- The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models.Journal of experimental & clinical cancer research : CR · 2021Article
- Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.Scientific reports · 2021Article
- Modeling Cancer Using Zebrafish Xenografts: Drawbacks for Mimicking the Human Microenvironment.Cells · 2020Review
- Knockdown of Matrix Metallopeptidase 9 Inhibits Metastasis of Oral Squamous Cell Carcinoma Cells in a Zebrafish Xenograft Model.BioMed research international · 2020Article
- A biomimetic 3D model of hypoxia-driven cancer progression.Scientific reports · 2019Article
- Article
- Myxofibrosarcoma primary cultures: molecular and pharmacological profile.Therapeutic advances in medical oncology · 2017Article
- Management and potentialities of primary cancer cultures in preclinical and translational studies.Journal of translational medicine · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Chiara LiveraniOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Federico La MannaOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Arwin GroenewoudDepartment of Molecular Cell Biology, Institute of Biology, Leiden University, Sylviusweg 72, Leiden 2333BE, The Netherlands.
Laura MercataliOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Gabri Van Der PluijmLeiden University Medical Center, Department of Urology, J-3-100, Albinusdreef 2, Leiden 2333ZA, The Netherlands.
Federica PieriPathology Unit, Morgagni-Pierantoni Hospital, Forlì 47121, Italy.
Davide CavaliereUnit of Surgery and Advanced Oncologic Therapies, Morgagni-Pierantoni Hospital, Forlì 47121, Italy.
Alessandro De VitaOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Chiara SpadazziOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Giacomo MiserocchiOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Alberto BongiovanniOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Federica RecineOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Nada RivaOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Dino AmadoriOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy.
Ennio TasciottiDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
Ewa Snaar-JagalskaDepartment of Molecular Cell Biology, Institute of Biology, Leiden University, Sylviusweg 72, Leiden 2333BE, The Netherlands.
Toni IbrahimOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola 47014, Italy toni.ibrahim@irst.emr.it.ORCID http://orcid.org/0000-0003-0259-4167
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived specimens are an invaluable resource to investigate tumor biology. However,
Indexed as
Collagen scaffoldsNear-patient modelsPrimary culturesZebrafish
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.